Glaxo takes a big blow as 'son of Advair' fails to extend COPD patients' lives

The company and its partner, Theravance, was strongly hoping that the asthma/COPD medication Breo would shine where other such drugs have failed by demonstrating a survival benefit. 

By Nicole Gray • Sept. 9, 2015

Novartis to join forces with Google, launch human tests for 'smart' contacts

Think of it as "auto-focus" for aging eyes.

By Sy Mukherjee • Sept. 8, 2015

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

New study claims Pfizer's Chantix not linked to depression, heart attacks after all

The controversial anti-smoking medication got a big boost from researchers in the U.K. But will it be enough to convince regulators that it's safer than once thought?

By Nicole Gray • Sept. 8, 2015

A big win for AZ as FDA clears Brilinta for long-term use

Brilinta (ticagrelor) was approved in 2011 for secondary prevention of acute coronary syndrome (ACS) events for up to one year.

By Nicole Gray • Sept. 8, 2015

Bristol-Myers is testing out a dual-threat Opdivo/Yervoy lung cancer combo

It's proven safe so far in early stage trials. But just how much of an improvement will it be over standalone therapy with the rock star Opdivo?

By Nicole Gray • Sept. 8, 2015

Bayer lines up a phase III trial for its dual-threat heart failure hopeful

Researchers are evaluating finerenone for treatment of chronic heart failure and diabetic kidney disease. 

By Nicole Gray • Aug. 31, 2015

Asterias stem cell therapy shows promise in spinal cord injury patients

The trial was small, but the results were promising.

By Nicole Gray • Aug. 31, 2015

An experimental anti-cholesterol drug could outperform approved PCSK9 meds

Watch out, Amgen and Sanofi/Regeneron.

By Nicole Gray • Aug. 31, 2015

J&J/Genmab unveil promising data for a potential multiple myeloma superstar

Daratumumab made waves at the American Society of Clinical Oncology meeting earlier this summer.

By Nicole Gray • Aug. 27, 2015

Novo jumping into phase III trials for major oral diabetes candidate

If approved, oral semaglutide will become the first non-injectable GLP-1 agonist. 

By Nicole Gray • Aug. 27, 2015

Could an aspirin a day keep colon cancer away?

Taking low-dose aspirin daily for at least five years reduces the risk of colorectal cancer by 27%, according to a new Danish study. 

By Nicole Gray • Aug. 26, 2015

Study: Common beta blockers can extend ovarian cancer patients' lives

In a retrospective study of women with ovarian cancer, taking non-selective beta blockers increased survival by an average of four years. 

By Nicole Gray • Aug. 25, 2015

US Army testing drug to protect soldiers' hearing

In 2013, tinnitus (consistent ringing in the ers) and hearing loss were the most prevalent service-connected disabilities for veterans.

By Nicole Gray • Aug. 24, 2015

Excitement over Jardiance may come at Merck's expense

A recent study suggested that Lilly/BI's Jardiance could be the first diabetes med to cut CVD risk.

By Nicole Gray • Aug. 24, 2015

Rare disease companies' existential challenge: Patient enrollment

Three companies are recruiting patients with Nieman Pick Type C (NPC), a very rare and deadly disease, for clinical trials.

By Nicole Gray • Aug. 21, 2015

Lilly/BI's Jardiance could be the first diabetes med to cut heart attack, stroke risk

In a large clinical study, people with diabetes who were treated with the drug had significantly fewer cardiac deaths and non-fatal heart attacks or strokes, compared with patients treated with standard of care. 

By Nicole Gray • Aug. 21, 2015

Intarcia's diabetes pump bests Merck's Januvia in head-to-head trial

This could be a big deal for the diabetes market. 

By Nicole Gray • Aug. 19, 2015

Kite Pharma does damage control, quashes drug-induced patient death rumors

Arie Belldegrun, Kite's CEO, reassured investors that negative rumors about an early-stage KTE-C19 trial were false. 

By Nicole Gray • Aug. 18, 2015

Roche's immunotherapy hopeful keeps rolling, this time in phase II lung cancer trial

Atezolizumab is being tested in almost a dozen phase III studies.

By Nicole Gray • Aug. 18, 2015

To reinflate lung portfolio, Glaxo needs Breo to shine where Advair failed

The company hopes that results from a massive trial will set Breo apart from other COPD meds by showing a survival benefit. 

By Sy Mukherjee • Aug. 14, 2015

Avalanche shares continute to fall off a cliff as company ditches eye drug trial

It's back to the preclinical drawing board for the investigational wet AMD drug. 

By Sy Mukherjee • Aug. 14, 2015

AbbVie, Genentech to seek US approval of potential blockbuster leukemia med

AbbVie/Roche's venetoclax is being tested in chronic lymphocytic leukemia (CLL) patients with a gene mutation that slashes survival rates. 

By Sy Mukherjee • Aug. 12, 2015

Clovis & Genentech team up to test out a promising lung cancer combo

The companies want to see if the dual therapy using an EGRF inhibitor and a PD-L1 blocker can be more effective in treating NSCLC patients. 

By Sy Mukherjee • Aug. 12, 2015

Hat trick: AstraZeneca cuts its 3rd cancer drug deal in a week

AZ is now officially on a cancer drug roll with this latest deal with Inovio.

By Randy Lilleston • Aug. 10, 2015

CNS-focused US cannabis patch company raises $42M in IPO

Pennsylvania's Zynerba Pharma plans to move into clinical trials with cannabinoid-laced transdermal patches for treatment of epilepsy and other CNS disorders.

By Nicole Gray • Aug. 6, 2015